STOCK TITAN

X4 Pharmaceuticals Inc - XFOR STOCK NEWS

Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.

X4 Pharmaceuticals Inc (XFOR) is a clinical-stage biopharmaceutical company pioneering oral therapies targeting the CXCR4 pathway to treat rare immunodeficiency disorders. This page provides a centralized hub for all official news, including press releases, clinical trial updates, and regulatory developments.

Investors and researchers will find timely updates on mavorixafor’s progress, partnership announcements, and financial disclosures. Content categories include clinical trial milestones, regulatory submissions, strategic collaborations, and earnings reports, ensuring comprehensive coverage of XFOR’s advancements.

Bookmark this page to stay informed about X4 Pharmaceuticals’ innovations in rare disease therapeutics, designed to address unmet medical needs through precision immunology.

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) has announced an underwritten public offering of its common stock and accompanying warrants. The offering, conducted by Piper Sandler, Stifel, and Cantor, includes a 30-day option for underwriters to purchase additional shares. The offering's completion is subject to market conditions, and no assurance is provided regarding the final terms. X4 is focused on developing mavorixafor, a treatment for immune system diseases, particularly chronic neutropenic disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.17%
Tags
-
Rhea-AI Summary

X4 Pharmaceuticals announced positive top-line results from its Phase 3 clinical trial (4WHIM) of mavorixafor for WHIM syndrome. The trial met its primary endpoint, demonstrating clinical superiority over placebo in increasing absolute neutrophil counts (P < 0.0001) and absolute lymphocyte counts (P < 0.0001). Mavorixafor was well tolerated, with no serious adverse events reported. Following the trial, over 90% of participants chose to continue treatment, highlighting its potential. The company aims to meet U.S. regulatory authorities in early 2023 for further steps towards regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.92%
Tags
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced management's participation in a fireside chat at the Stifel Healthcare Conference on November 15, 2022, at 3:00 PM ET. The event will be streamed live on their website, with an archive available for 90 days post-event. X4 Pharmaceuticals focuses on novel therapies for immune system diseases, including their leading candidate, mavorixafor, a small-molecule therapy targeting CXCR4, currently in global Phase 3 trials for WHIM syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Scorpion Therapeutics has announced the formation of a Clinical Scientific Advisory Board (Clinical SAB) to enhance its Precision Oncology 2.0 strategy. This board comprises esteemed physician-scientists specialized in cancer treatment and development. The Clinical SAB will provide insights to expedite the company's lead programs, including STX-478 and STX-721, aimed at advancing toward investigational new drug applications in 2023. CEO Axel Hoos expressed optimism about the expertise of the members and their potential impact on improving cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
management
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced the issuance of inducement awards for new employees under the 2019 Inducement Equity Incentive Plan. On November 3, 2022, the company granted options to purchase 410,000 shares of its common stock, with 341,000 shares awarded to the new Chief Commercial Officer, Mark Baldry. The options have a ten-year term and an exercise price of $1.89 per share, matching the closing price on the grant date. Vesting occurs over four years, contingent on continued employment. X4 focuses on developing therapies for immune system diseases, including its lead candidate mavorixafor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) reported its third-quarter 2022 financial results, highlighting key advancements in its lead candidate, mavorixafor, after positive Phase 1b data in chronic neutropenic disorders. The company anticipates top-line results from the pivotal Phase 3 WHIM syndrome trial in Q4 2022, potentially leading to a U.S. regulatory submission in H2 2023. X4 ended Q3 2022 with $81.1 million in cash, supporting operations into Q3 2023. Despite a net loss of $21.6 million, X4 is focused on advancing mavorixafor as a new treatment option for underserved patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
Rhea-AI Summary

X4 Pharmaceuticals has appointed Mark Baldry as the new Chief Commercial Officer, effective November 3, 2022. Baldry brings over 30 years of experience in launching specialty pharmaceuticals and will oversee pre-commercial and product launch efforts for mavorixafor, X4's lead candidate for chronic neutropenic disorders, including WHIM syndrome. The company is preparing to reveal Phase 3 data from the mavorixafor clinical trial, which holds significant potential as a first line therapy. This leadership change may strengthen the company’s market position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
management
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) will report its Q3 financial results on November 3, 2022. The company will also host a conference call at 8:30 a.m. ET to discuss key milestones, particularly the results from its Phase 3 trial of mavorixafor for WHIM syndrome. This investigational therapy, a small molecule antagonist of CXCR4, aims to improve white blood cell mobilization for various immune system diseases. X4 is focusing resources on chronic neutropenic disorders and has additional studies ongoing for mavorixafor. More details can be found on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
conferences earnings
-
Rhea-AI Summary

X4 Pharmaceuticals announced promising results from its Phase 1b trial of mavorixafor, targeting chronic neutropenia (CN). All 25 participants in the study responded positively, achieving significant increases in absolute neutrophil count (ANC). Notably, the treatment normalized ANC levels in 100% of the neutropenic subjects, suggesting mavorixafor could become the first oral therapy for CN disorders. The trial included idiopathic, cyclic, and congenital variants, with an estimated patient population of 50,000 in the U.S. Further studies are planned to confirm the long-term efficacy and safety of mavorixafor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.13%
Tags
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) will host a webcast on September 27, 2022, at 8:00 a.m. ET to discuss data from its Phase 1b trial of mavorixafor in patients with neutropenia. The event will include insights from patients and clinical experts about treatment needs. Management will present data on 25 fully enrolled patients and explore mavorixafor's potential beyond WHIM syndrome. A Q&A session will follow. The trial aims to assess the safety and tolerability of mavorixafor, a novel small-molecule therapy for immune system diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.61%
Tags
conferences clinical trial
X4 Pharmaceuticals Inc

Nasdaq:XFOR

XFOR Rankings

XFOR Stock Data

33.13M
161.09M
1.27%
59.2%
5.56%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON